Prediction of pathologic complete response to sequential paclitaxel and 5‐fluorouracil/epirubicin/cyclophosphamide therapy using a 70‐gene classifier for breast …
Y Naoi, K Kishi, T Tanei, R Tsunashima, N Tominaga… - Cancer, 2011 - Wiley Online Library
BACKGROUND. Sequential administration of paclitaxel plus combined fluorouracil,
epirubicin, and cyclophosphamide (P‐FEC) is 1 of the most common neoadjuvant …
epirubicin, and cyclophosphamide (P‐FEC) is 1 of the most common neoadjuvant …
Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast …
Y Naoi, K Kishi, T Tanei, R Tsunashima, N Tominaga… - Cancer, 2011 - europepmc.org
Background Sequential administration of paclitaxel plus combined fluorouracil, epirubicin,
and cyclophosphamide (P-FEC) is 1 of the most common neoadjuvant chemotherapies for …
and cyclophosphamide (P-FEC) is 1 of the most common neoadjuvant chemotherapies for …
Prediction of pathologic complete response to sequential paclitaxel and 5‐fluorouracil/epirubicin/cyclophosphamide therapy using a 70‐gene classifier for breast …
Y Naoi, K Kishi, T Tanei, R Tsunashima, N Tominaga… - Cancer, 2011 - infona.pl
BACKGROUND. Sequential administration of paclitaxel plus combined fluorouracil,
epirubicin, and cyclophosphamide (P‐FEC) is 1 of the most common neoadjuvant …
epirubicin, and cyclophosphamide (P‐FEC) is 1 of the most common neoadjuvant …
[引用][C] Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for …
Y Naoi, K Kishi, T Tanei, R Tsunashima, N Tominaga… - Cancer, 2011 - cir.nii.ac.jp
Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide
therapy using a 70-gene classifier for breast cancers | CiNii Research CiNii 国立情報学 …
therapy using a 70-gene classifier for breast cancers | CiNii Research CiNii 国立情報学 …
[引用][C] Prediction of Pathologic Complete Response to Sequential Paclitaxel and 5-Fluorouracil/Epirubicin/Cyclophosphamide Therapy Using a 70-Gene Classifier for …
Y NAOI, K KISHI, T TANEI, R TSUNASHIMA… - Cancer, 2011 - pascal-francis.inist.fr
Prediction of Pathologic Complete Response to Sequential Paclitaxel and 5-Fluorouracil/
Epirubicin/Cyclophosphamide Therapy Using a 70-Gene Classifier for Breast Cancers CNRS …
Epirubicin/Cyclophosphamide Therapy Using a 70-Gene Classifier for Breast Cancers CNRS …
Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast …
Y Naoi, K Kishi, T Tanei, R Tsunashima… - Cancer, 2011 - pubmed.ncbi.nlm.nih.gov
Background Sequential administration of paclitaxel plus combined fluorouracil, epirubicin,
and cyclophosphamide (P-FEC) is 1 of the most common neoadjuvant chemotherapies for …
and cyclophosphamide (P-FEC) is 1 of the most common neoadjuvant chemotherapies for …